Newsbenzinga
Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug
· Published
Article summary
Elicio shares complete response data for ELI-002 7P in KRAS pancreatic cancer and plans combination studies after mixed Phase 2 results.
An excerpt from the original article.
Comments —
Loading comments…